Novel long-acting β 2-agonists (eg indacaterol, vilanterol, olodaterol and carmoterol) and
muscarinic antagonists (eg tiotropium, aclidinium, glycopyrronium and umeclidinium …

COPD is characterized by progressive airflow obstruction which does not fully reverse to
inhaled or oral pharmacotherapy. The management of patients with COPD has taken a …

Indacaterol is a novel, inhaled, long-acting β2-agonist providing 24-h bronchodilation with
once-daily (od) dosing in patients with COPD. In this double-blind, incomplete block …

Anticholinergic agents have important uses as bronchodilators for the treatment of
obstructive airway diseases, both asthma and, more particularly, chronic obstructive …

This book provides a state-of-the-art account by academic respiratory physicians and senior
pharmaceutical industry personnel on the development of new drugs for asthma, allergy and …

Chronic obstructive pulmonary disease (COPD) is a common disabling disease
characterized by progressive airflow obstruction. Great efforts were spent in the …

Bronchodilators are the cornerstone of symptomatic treatment for all chronic obstructive
pulmonary disease (COPD) severity stages when administered on a regular basis to prevent …

There is unequivocal evidence that the combination of an inhaled corticosteroid (ICS)—ie
glucocorticoid—and an inhaled long‐acting β2‐adrenoceptor agonist (LABA) is superior to …

The long-acting inhaled bronchodilators available for use in chronic obstructive pulmonary
disease (COPD) vary in their pharmacological class (β 2-adrenergic agonist or …

The β-adrenoceptor agonists (β-agonists) have been used to relieve bronchoconstriction for
at least 5000 years. β-agonists are based on adrenaline and early forms, such as …